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Abstract
Background: HIV and HCV infections have become the leading global public-health threats. Even more
remarkable, HIV-HCV co-infection is rapidly emerging as a major cause of morbidity and mortality throughout the
world, due to the common rapid mutation characteristics of the two viruses as well as their similar complex
influence to immunology system. Although considerable progresses have been made on the study of the infection
of HIV and HCV respectively, few researches have been conducted on the investigation of the molecular
mechanism of their co-infection and designing of the multi-target co-inhibitors for the two viruses simultaneously.
Results: In our study, a multi-target Quantitative Structure-Activity Relationship (QSAR) study of the inhibitors for
HIV-HCV co-infection were addressed with an in-silico machine learning technique, i.e. multi-task learning, to help
to guide the co-inhibitor design. Firstly, an integrated dataset with 3 HIV inhibitor subsets targeted on protease,
integrase and reverse transcriptase respectively, together with another 6 subsets of 2 HCV inhibitors targeted on
NS3 serine protease and NS5B polymerase respectively were compiled. Secondly, an efficient multi-target QSAR
modelling of HIV-HCV co-inhibitors was performed by applying an accelerated gradient method based multi-task
learning on the whole 9 datasets. Furthermore, by solving the L-1-infinity regularized optimization, the Drug-like
index features for compound description were ranked according to their joint importance in multi-target QSAR
modelling of HIV and HCV. Finally, a drug structure-activity simulation for investigating the relationships between
compound structures and binding affinities was presented based on our multiple target analysis, which is then
providing several novel clues for the design of multi-target HIV-HCV co-inhibitors with increasing likelihood of
successful therapies on HIV, HCV and HIV-HCV co-infection.
Conclusions: The framework presented in our study provided an efficient way to identify and design inhibitors
that simultaneously and selectively bind to multiple targets from multiple viruses with high affinity, and will
definitely shed new lights on the future work of inhibitor synthesis for multi-target HIV, HCV, and HIV-HCV
co-infection treatments.
Background
Human immunodeficiency virus (HIV-1) is the cause of
acquired immunodeficiency syndrome (AIDS) which has
infected more than 60 million people around the world
[1,2]. Meanwhile, Hepatitis C virus (HCV), which is served
as a serious cause of chronic liver disease, has infected
150-200 million people worldwide [3]. Nowadays HIV and
HCV infections have become global public-health threats.
Even more remarkable, HIV-HCV co-infection is rapidly
emerging as a major cause of morbidity and mortality
throughout the world, since that both of the viruses share
the same routes of transmission [3,4]. It is shown that
infection with the HCV is the most common co-infection
in people with HIV, and hepatitis C is categorized as an
HIV-related opportunistic illness. Complications related to
HIV-HCV co-infection are becoming an increasingly
important medical issue [4].
The current strategies for developing HIV/HCV antiviral
agents depend essentially on disrupting the replication of
the 2 viruses, and various inhibitors have been designed to
target and block the functions of the enzymes necessary in
the replication cycle of HIV/HCV. Among them, HIV
inhibitors commonly target on protease, integrase and
reverse transcriptase (RT), while HCV inhibitors target on
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inhibitors have been considered as attractive targets for
therapeutic intervention in HIV/HCV infected patients.
For HIV and HCV therapy, single antiretroviral drug,
alone or in simply combination with each other, is no
longer recommended for clinical use owing to (1) the
complicated infection mechanism of these two viruses; (2)
the severe side effects of the joint using and (3) the rapid
emergence of drug-resistant strains after initiation of ther-
apy. Hence, drugs targeting on different targets with high
therapeutic and reduced side effects are expected to be
more effective at suppressing viral growth. For HIV, The
multi-target antiretroviral drugs can succeed in inhibiting
several HIV proteins simultaneously and efficiently. There
has existed several pioneeringw o r ki nm u l t i - t a r g e td r u g
discovery for HIV infection, such as the multi-target anti-
retroviral drug Cosalane [13], which was developed to
inhibit several HIV-1 proteins simultaneously. Compared
to HIV, the multiple target HCV drug treatment is still in
its infancy. Nevertheless, the combination use of single-
target HCV drugs has become a new chance in this field,
such as the combination using of NS5B polymerase inhibi-
tor (GS-9190) and NS3 protease inhibitor (GS-9256),
which were shown to be safe, well-tolerated and show
dose dependant antiviral activity [19,20].
Since for both HIV and HCV the small-molecule com-
pounds used to design the drugs are needed to be assayed
in vitro and in vivo, the popular in-silico Quantitative
Structure-Activity Relationship (QSAR) modelling is
applied extensively in HIV/HCV inhibitor studies due to
its charming “black-box” characteristics as well as its well
prediction ability. Normally the QSAR modelling can be
viewed as a computational technique to elucidate a quanti-
tative correlation between chemical structure and biologi-
cal activity [21]. Recently, considerable QSAR studies have
been made for HIV/HCV inhibitors studies [5-18]. How-
ever, these studies were mainly focused on specific types
of targets or specific diseases individually. Few studies
have been performed on the multi-target HIV-HCV co-
infection QSAR modelling. Although the ways in which
co-infection with HIV and HCV affect the body are still
poorly understood, it has been indicated that both HIV-1
Protease and HCV NS3 Protease are responsible for cleav-
ing the viral polyproteins during the course of their action
to produce the individual proteins of the mature viruses.
Similarly, HIV-1 reverse transcriptase and HCV NS5B can
be affected by either nucleoside inhibitor that terminates
nucleic acid synthesis or non-nucleoside inhibitor that
impairs enzymatic function [22,23]. All these evidences
have indicated that it is possible to design certain inhibi-
tors that aim at both HIV targets and HCV targets simul-
taneously. From this point of view, multi-target co-
infection QSAR modelling for HIV and HCV is attractive
and promising, due to that it is easy to achieve and
expected to provide useful clues on how to synthesize
such co-inhibitors with improved affinities.
In our previous study, we presented a multi-target
QSAR modelling on HIV-1 inhibitors individually [31]. In
this study we desire to extend this model to investigate the
multi-target QSAR modelling of HIV and HCV jointly and
simultaneously, and aim at providing useful clues on the
design of HIV-HCV co-inhibitors. The QSAR modelling
of HIV-HCV co-infection inhibitors (co-inhibitors for
short) was addressed by applying an efficient accelerated
gradient method based multi-task learning (MTL) model
provided by us formerly in machine learning community
[24]. QSAR studies were performed on 9 datasets of HIV
and HCV inhibitors. By using our MTL framework, the
correlations among different set of inhibitors were utilized
a n da ne f f i c i e n tm u l t i - t a r g e tQ S A Rm o d e l l i n go fH I V -
HCV co-inhibitors was obtained. According to the impor-
tance of each descriptor in QSAR model, the Drug-like
index (DL) features [25] for inhibitor description were
ranked, and a drug structure-activity simulation were per-
formed to investigate the relationships between compound
structures and binding affinities based on the ranked
molecule descriptors.
Methods
A Dataset
Our integrated dataset contains 3 kinds of HIV target sub-
sets and 6 kinds of HCV target subsets, which were com-
piled from a thoroughly literature reviewing, consisting of
inhibitors with their binding affinities on HIV protease,
integrase and reverse RT, as well as HCV NS3 and NS5B
respectively. This data provided the first time a compre-
h e n s i v ed a t as o u r c ef o rm u l t i - target HIV-HCV co-infection
QSAR study. In our study, these inhibitors are correspond-
ingly referred as (1) protease inhibitors, which prevent HIV
from processing and packaging new virulent viral particles,
(2) integrase inhibitors, which inhibit the proviral DNA to
insert into the host cell genome, (3) non-nucleoside reverse
transcriptase inhibitors (NNRTI), which inhibit the virus by
preventing the transcribing of its genomic DNA into pro-
viral DNA for incorporation into the host cell DNA, (4)
NS3 serine protease inhibitors, which prevent polyprotein
processing and restore the hepatocytes innate antiviral
response, and (5) NS5B polymerase inhibitors, which pro-
hibit the synthesis of RNA strands of HCV. All the
enzymes affected by these inhibitors have been reported as
the most important targets for chemotherapeutic agents
against the diseases caused by HIV/HCV. General descrip-
tions of inhibitors for these targets were listed in Table 1.
Similar to our previous study [31], the inhibitors were
represented with 2 kinds of feature spaces referring to
32-dimensional General Descriptor (GD) features and
28-dimensional Drug-like index (DL) features. Although
there are numerous types of descriptors to describe a
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Page 2 of 20chemical compound, none of a set of descriptors can
guarantee to behave overwhelming better than others.
Therefore, the widely applicable set of descriptors, i.e.,
the GD [25] was selected, together with the DL descrip-
tor [26,27] as a complement.
Detailed biological meaning of GD and DL descriptors
can be referred in our previous work [31]. It should be
noted that: (1) normally, general descriptors characterize
physical prosperities of compounds, while drug-like
index descriptors characterize simple topological indices
of compounds. These two kinds of descriptors are
expected to present a comprehensive description of the
compounds from the views of their intrinsic characteris-
tics as well as their drug-like properties. (2) The GD
descriptor is generated in a hybridized way thus its cur-
rent features haven’t kept their original means for com-
pound structure description. Therefore it cannot be
biologically explained easily. On the other side, DL
holds its original meanings, thus will be applied in our
following feature ranking and explanations.
It was shown in Table 1 that the inhibitor activity of
the molecules were measured with EC50, IC50 or PKi,
which are the most commonly used measurements of
the compound inhibitions [28]. EC50 (half maximal
effective concentration) refers to the concentration of a
drug, antibody or toxicant which induces a response
halfway between the baseline and maximum after some
specified exposure time, while IC50 (half maximal inhibi-
tory concentration) refers to the concentration it needed
to inhibit a given biological process or component of a
process by half. IC50 can be converted to the PKi mea-
surement by the Cheng-Prusoff equation:
PKi = −log
IC50
1+
[L]
KD
(1)
Where [L] is the concentration of free radio ligand
used and KD is its equilibrium dissociation constant for
the receptor [29].
It should be noted that the QSAR data were provided by
different research groups under different platforms/proto-
cols with different activity measurements. Normally QSAR
modeling achieved by such single target data is often not
reliable due to the insufficiency of samples. However,
since we want to investigate the multi-target QSAR rela-
tionship of the HIV-HCV co-infection, these data can be
integrated in an elegant multi-target QSAR model taking
the advantages of the multi-task learning [30], which
would expect to exploit the possible synergies between dif-
ferent datasets and obtain a better QSAR model to guide
the synthesis of certain inhibitors with enhanced activities
for HIV and HCV simultaneously. Details will be shown in
the following.
B Methodology
Computational framework for multi-target modelling
The general computational pipeline for our study was pre-
sented in Figure 1. In our previous study we have pre-
sented the first time a multi-task learning algorithm for
cross-platform siRNA efficacy prediction [30], and also uti-
lized such MTL-based model for feature-selection in HIV-
1Q S A Rm o d e l i n g[ 3 1 ] .I th a sb e e np r o v e nt ob em o r e
effective than learning each QSAR modeling on single tar-
get independently [31]. Some latent commonalities across
tasks can be exploited through MTL, which is expected to
boost the learning performance of each single task.
In current study, a novel accelerated gradient descent
algorithm based MTL model was performed for multi-
target QSAR modeling on our integrated datasets simul-
taneously. Our in-house experiments indicated that this
MTL model is more efficient than our formerly adopted
one for multi-target QSAR modeling [31] and it is scaled
up well for large scale QSAR modeling in both conver-
gence speed and learning accuracy. A joint L-1-infinity
regularization based feature selection procedure was per-
formed on the DL feature space to reveal the most com-
mon features across multi-target HIV-HCV co-infection
QSAR modeling. Based on such model, a drug structure-
activity simulation for investigating the relationships
Table 1 Dataset descriptions
Dataset ID Target type Number of inhibitors Activity measurement
1 HIV-1 Reverse Transcriptase 79 EC50 [37]
2 HIV-1 Integrase 213 IC50 [6]
3 HIV-1 Protease 106 pKi [1]
4 HCV NS5B Polymerase 67 IC50 [7]
5 HCV NS5B Polymerase 45 IC50 [8]
6 HCV NS5B Polymerase 41 EC50 [9]
7 HCV NS3 Serine Protease 42 pKi [10]
8 HCV NS3 Serine Protease 53 pKi [9]
9 HCV NS3 Serine Protease 34 EC50 [11]
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further presented to validate our selected important fea-
tures for efficient co-inhibitor synthesis and design.
Multi-task learning for QSAR modelling of HIV-HCV co-
inhibitors
Multi-task learning has been developed in machine
learning research to situations where multiple related
learning tasks are accomplished together. It has been
proven to be more effective than learning each task
independently when there are explicit or hidden interre-
lationship among the tasks that can be exploited. The
intuition underlying the framework is that the multiple
related tasks can benefit each other by sharing the data
and features across the tasks, which can often boost the
learning performance of each single task [30]. Also it
provides an efficient mechanism for cross-task feature
selection, thus could uncover the common dominate
features for all the tasks simultaneously. Such computa-
tional ability is inherently suitable for our multi-target
QSAR modeling, in which each single QSAR model
could be viewed as a task and the leading features for
synthesizing co-inhibitors with improved activity will be
identified under such schema.
It should be noted that the QSAR modelling is the pro-
cess by which chemical structure is quantitatively corre-
lated with a well-defined process, such as biological
activity or chemical reactivity. And this procedure is gen-
erally formulated as a regression model [32] to predict
the compound activity based on a given set of molecule
descriptors. Although various statistical and machine
learning methods have been proposed in the last few
years for QSAR modeling [32], few studies have been
tried in the multi-target QSAR scenario. In our study the
multi-target QSAR modeling will be elegantly formulated
as a multi-task regression framework to reveal useful
clues for multi-target drug screening and synthesizing for
HIV-HCV co-infections.
Basically in our multi-target modeling, assuming the
datasets contains N tuples, zi =( x i, yi, ki)f o ri={ 1 . . . N},
where xi Î R
d is the inhibitor descriptor and ki Î {1...
M} is the indicator specifying to which of the M task
the example (xi, yi) corresponds to. A critical issue in
this case is to learn a set of sparse functions across
these tasks for activity regression. Specifically, the fea-
tures will be represented as GD or DL. yi is the corre-
sponding inhibitor binding affinity. Our goal is to
predict the target binding affinity from a set of com-
pound with known affinity by learning M linear regres-
sions of the form wT
kx. In our study the following
square loss function is adopted:
ls(z,W)=( y − wT
k · x)2, (2)
where z =( x ,y, k), W =[w1,w 2,. . . ,w M] Î R
d×Mand
W
j be the jth row of W.
In sparse MTL for features selection, we enforce the
joint sparsity across different tasks by adding the l1,∞
norm of the matrix W to the square loss function,
which leads to only a few non-zero rows of W, and thus
the corresponding features will be used for prediction.
In short, the optimization target function is defined as
F(W), and we want to minimized the following function
as:
min
W
F(W)=f(W)+ψ(W), (3)
Figure 1 The general computational framework for multi-target QSAR modelling of HIV-HCV co-inhibitors.
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f(W)=
1
N
N 
i=1
ls(zi,W) (4)
and
ψ(W)=λ W 1,∞ (5)
The l1,∞ norm of the matrix W is defined as:
||W||1,∞ =
d 
j=1
||Wj||∞ =
d 
j=1
max
1≤k≤M
|Wjk|. (6)
The first term in Equation (3) is the average of the
empirical error across the tasks. The second term is the
L-1-infinity regularization term that works on feature
selection task in MTL, which can yield joint sparsity on
both the feature level and task level and can lead to a
more sparse solution [24].
As the main difficulty for solving the l1,∞ regularized
formulation in formation (6) lies in the non-smooth
property of the l1,∞ regularizer, we present an acceler-
ated gradient descent algorithm with the convergence
rate O (1/t
2) by a variation of Nesterov’s method calling
a black-box oracle in the projection step at each itera-
tion [24]. By exploiting the structure of the l1,∞ ball, we
find the black-box oracle can be efficiently solved by a
simple sorting procedure. Compared with Nesterov’s
algorithm, our method is suitable for large-scale multi-
task learning problem since it only utilizes the first
order information and is very easy to implement.
Experiment results in our previous study have shown
that our method significantly outperforms the most
state-of-the-art methods in both convergence speed and
learning accuracy [25].
Details of the accelerated gradient descent algorithm
were presented in Algorithm 1. The generalized gradient
update step was defined as following:
QL(W,Wt)=f(Wt)+

W − Wt,∇f(Wt)

+
L
2
||W − Wt||2
F + λ||W||1,∞
qL(Wt) = argmin WQL(W,Wt) (7)
where ||·||F denotes the Frobenius norm and 〈A, B〉 =
Tr(A
T B) denotes the matrix inner product.
Algorithm 1: Accelerated Gradient Algorithm
Initialization: L0 >0 ,h >1 ,W0 Î R
d × M, V0 = W0
and a0 =1 .
Iterate for t = 0, 1, 2,... until convergence of Wt:
1) Set L = Lt
2) While F(qL(Vt)) >QL(qL(Vt), Vt)
L = h L
3) Set Lt+1 = L and compute
Wt+1 = argmin WQLt+1(W,Vt)
at+1 =
2
t +3
δt+1 = Wt+1 − Wt
Vt+1 = Wt+1 +
1 − at
at
at+1δt+1
In addition, we suggest a look-ahead stopping criter-
ion for Algorithm 1 by firstly fixing a step size h and in
each iteration t calculating the following ratio:
κ =
max
t≤i≤t+h
F(Wi) − min
t≤i≤t+h
F(Wi)
max
t≤i≤t+h
F(Wi)
. (8)
We stop the procedure when  ≤ τ where τ is a pre-
fixed constant.
Then, we discuss how to solve the generalized gradi-
ent update efficiently. Rewrite formulation (7), we obtain
that:
qL(Vt) = argmin(
1
2
||W − (Wt −
1
L
∇f(Wt))||2
F +
λ
L
||W||1,∞) (9)
For the sake of simplicity, we denote
(Wt −
1
L
∇f(Wt)) as V and
λ
L
as  λ .F o re q u a t i o n( 9 )
the following form was taken:
qL(Vt) = argmin W

1
2
||W − V||2
F +
∼
λ||W||1,∞

= argmin
W1...Wd
d 
i=1

1
2
||Wi − Vi||2
2 +
∼
λ||Wi||∞

, (10)
where W
i, V
i denotes the i th row of the matrix W, V
respectively. Therefore, (10) can be decomposed into d
separate subproblems of dimension M.
For each subproblem:
min
w
1
2
||w − v||2
2 + λ||w||∞ (11)
Since the conjugate of a quadratic function is still a
quadratic function and the conjugate of the norm is the
barrier function, the dual of (11) takes the following
form:
min
α
1
2
||α − v||2
2 s.t.||α||1 ≤ ˜ λ (12)
and the vector of dual variables a satisfies the relation
a = v - w. Equation (12) can be solved by an efficient pro-
jection onto the ball l1 according to [33]. With the primal
dual relationship, we present Algorithm 2 for solving
(11):
Algorithm 2: Algorithm for projection onto the l∞
ball
Input: A vector v Î R
M and a scalar  λ>0
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Page 5 of 201) If ||v||1 ≤ λ , set w = 0. Return.
2) Let ui be the absolute value of vi,i . e .ui =| vi|. Sort
vector u in the decreasing order: u1 ≥ u2 ≥ ... ≥ uM
3) Find ˆ j =m a x

j : ˜ λ −
j
r=1
	
ur − uj


> 0

Output: wi =s i g n ( vi)min(|vi|,(
ˆ j
r=1 ur − ˜ λ)/ˆ j), i = 1...M
Feature selection across multiple tasks
It has been demonstrated that the coefficient among dif-
ferent tasks will achieve zeros simultaneously by using
the l1,∞ norm regularization with the “grouping” effect
[24]. So the l1,∞ regularization can provide an efficient
w a yt oe v a l u a t et h ej o i n tf e a t u r ei m p o r t a n c ei nH I V -
HCV co-inhibitor design across multiple target enzymes.
The basic idea behind this joint feature selection proce-
dure is that the parameter W o u t p u t t e df r o mt h ea l g o -
rithm for projection onto the l1,∞ ball would present a
ranking of the features based on their joint importance
across multiple tasks. Formally, based on the parameter
W derived from Algorithm 2, we can obtain bi accord-
ing to the following equation
βi =
||Wi||2
||W||2,1
,i = 1,...d (13)
The value of bi indicates the weight of the corre-
sponding feature, which gives us a quantitative way to
evaluate the importance of various features for HIV-
HCV co-inhibitor design and synthesize.
Domain of applicability of the model
The domain of application (DOA) is an important issue
for QSAR model which is used for estimating the relia-
bility in the prediction of a new compound [34]. Those
molecules which fall out the domain may lead to unreli-
able predictions. Extent of extrapolation is a simple
method to define the DOA[35]. It is based on the value
of leverage hi define in equation (14) for each chemical
molecule:
hi = XT
i (XTX)−1Xi (14)
Where Xi is the row-vector descriptor of the query
compound, Xi is the n × k matrix containing k descrip-
tor values and n training samples. The superscript T
refers to the transpose of the matrix or vector. Gener-
ally, the warning leverage h* is fixed at 3 k/n, where n is
the number of training compounds, and k is the number
of descriptor. When a leverage is greater than the warn-
ing leverage h*, the predicted activity is the result of
substantial extrapolation of the model and, therefore, it
may not be reliable.
Based on the definition of leverage, Williams plot was
used in our study to visualize the DOA of the QSAR
model [35]. The Williams plot plots the standardized
cross-validated residuals (RES) versus leverage values (h),
and can be used to obtain an immediate and simple gra-
phical detection of both the response outliers (Y outliers)
and the structurally influential chemicals (X outliers) of a
model. Generally, the points with their values of Y axis
fall outside the 3s line (s is the standard residuals unit of
the compounds) can be referred as the Y outliers, while
the points with their values of X axis fall outside the
warning leverage h* line can be referred as the X outliers.
Multi-target HIV-HCV co-inhibitor design based on drug
structure-activity prediction
After the feature ranking together with the examination
of domain of application for multiple HIV-HCV drug
targets QSAR modelling, a drug structure-activity pre-
diction [27] was performed for the analysis of the multi-
ple drug data. The goal of this study is two folds: (1) It
is used to computationally validate the ranking result by
our multi-task feature selection, and (2) It provides sev-
eral useful modification strategies for further HIV-HCV
co-inhibitor design.
Our prediction pipeline is carefully designed as shown in
Figure 2. To be brief, the whole procedure is achieved by
the following steps: First, All the compounds used for our
multi-target QSAR study are gathered as the input, to gen-
erate their common scaffolds. If more than one scaffold is
presented, they are topologically aligned to produce a
common numbering system. Second, assigning the scaf-
f o l d sb ye n u m e r a t i n ga l lp o s s i b l es u b s t r u c t u r em a t c h e s ,
then minimizing a pair-wise energy term which leads to
the lowest possible diversity of implied R-group substitu-
ents, which is expected to provide a set of analogous sub-
stitution points. An examplei nt h i sc a s e( F i g u r e3 ) ,t h e
positions indicated by R1 for each molecule are, for this
example, considered analogous substitution points, as are
the positions indicated by R2. These positions have com-
mon meaning for the molecules, regardless of which of
these two scaffolds they are based on. Finally, the list of
hypothetical molecules, constructed from available ones, is
generated by enumerating all of the input molecules, and
Figure 2 Computational pipeline for structure-activity
simulation and hypothetical molecule generation.
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ent positions, with each of the R-groups that have been
observed in the analogous position for some other mole-
cule in the input dataset. The unique list of chimeric
molecules is then scored according to an estimate of prob-
ability, scaled and balanced to match the distribution of
activities found in the input set. The scores are scaled
such that a value of 0 indicates that the hypothetical mole-
cule is as likely to be active as an average molecule in the
input set, while positive values are more likely [27].
Based on this computational prediction pipeline, we
will identify what is the most efficient compound modifi-
cation strategy to improve the molecule affinity targeting
on multiple HIV-HCV enzymes. Also, these identified
Figure 3 An example of analogous substitution points.T h e
positions indicated by R1 for each molecule are considered
analogous substitution points as the positions indicated by R2.
Figure 4 RMSE comparison of QSAR modelling based on accelerated gradient descent based MTL with STL on 9 targets, described in
GD representation.
Liu et al. BMC Bioinformatics 2011, 12:294
http://www.biomedcentral.com/1471-2105/12/294
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ranking obtained under the multi-target QSAR paradigm.
Results and Discussions
Formulated as a multi-task regression problem, the
QSAR modelling of HIV-HCV co-inhibitors was per-
formed based on the accelerated gradient descent based
sparse multi-task learning. Root mean squared error
(RMSE) and squared correlation coefficient (R
2)w e r e
adopted as the performance evaluation for testing
results. The definitions of these statistical parameters
are provided as followed:
Root mean squared error (RMSE):
RMSE =


1
n
n 
i=1
e2
i (15)
where n is the number of predicted drug molecules
ei = yi − ˆ yi, is the difference between the observed
molecule affinity data and the fitted model
yi is the observed molecule affinity
ˆ yi is the predicted molecule affinity
Figure 5 RMSE comparison of QSAR modelling based on accelerated gradient descent based MTL with STL on 9 targets, described in
DL representation.
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2):
R2 =1−
SSerr
SStot
=1−

i
	
P
exp
i − Pcalc
i

2

i
	
P
exp
i − Pavg
2 (16)
where P
avg is the average value of P
exp
i over the n pre-
dicted molecule affinities.
Sparse MTL was trained jointly on 9 targets datasets as
indicated in Table 1 with 10%, 30%, 50%, 70% and 90% of
the whole data respectively. The trained model was then
applied for the affinity prediction of remaining data. We
run each experiment 10 times and output the average
RMSE and R
2. For each target, the output were calculated
based on single task learning (denoted as STL in the fig-
ure), multiple task learning on HCV or HIV (denoted as
HCV/HIV in the figure) and multiple task learning on all
the inhibitors (denoted as MTL-ALL in the figure). The
testing results were summarized in Figure 4, 5, 6 and 7,
denoting the scenarios of representation of compounds
with GD and DL respectively. The goal of this test was to
compare the performance of MTL and single-task learn-
ing (STL) in the QSAR modelling of HIV/HCV
inhibitors.
It is obvious that for both GD and DI feature space,
using multi-task learning for QSAR modelling is
Figure 6 R
2 comparison of QSAR modelling based on accelerated gradient descent based MTL with STL on 9 targets, described in GD
representation.
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Page 9 of 20superior to single-task learning on most target datasets,
with the evaluation of RMSE and R
2 and significant sta-
tistical confidence (data not shown). And the average
correlation coefficient for data prediction under MTL is
up to 0.6~0.7, which is a well-accepted QSAR results.
Such results proved that multi-task learning can dis-
cover the latent commonalities across different types of
inhibitors and take advantage of the synergy among
multiple tasks when the label data on each single task
are insufficient. These results also indicated that multi-
task learning provides an effective way to boost the
learning performance of each single task by exploiting
the available synergy between them, thus served as an
efficient paradigm for multi-target QSAR modelling.
In order to define the domain of applicability of our
QSAR model, the Williams plots were drew for each
QSAR model, based on MTL and STL with GD and DI
feature space respectively. For each dataset, 65% of the
whole data was chosen as the train data and the remains
were used as testing. The plots were summarized from
Figure 8, 9, 10 and 11. Each plot contains the com-
pounds represented as the training set (purple squares)
and test set (red squares). It can be clearly seen that
most of the compounds fall into their corresponding
Figure 7 R
2 comparison of QSAR modelling based on accelerated gradient descent based MTL with STL on 9 targets, described in DL
representation.
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Page 10 of 20Figure 8 Williams plots of 9 QSAR models based on MTL with Drug-like Descriptor.
Figure 9 Williams plots of 9 QSAR models based on STL with Drug-like Descriptor.
Liu et al. BMC Bioinformatics 2011, 12:294
http://www.biomedcentral.com/1471-2105/12/294
Page 11 of 20Figure 10 Williams plots of 9 QSAR models based on MTL with General Descriptor.
Figure 11 Williams plots of 9 QSAR models based on STL with General Descriptor.
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Page 12 of 20Table 2 A joint feature ranking of the DL compound descriptors
Features Ranking values
# of non-H 0.167148
# of 2-degree cyclic atoms 0.118946
degree of cyclization 0.100268
# of non-H polar bonds 0.056622
# of rotatable bonds 0.049770
# of carbons in cap fragments 0.047428
# of cap fragments 0.043447
# of 3-degree cyclic atoms 0.040664
# of N and O atoms 0.038882
# of H-bond acceptors 0.038103
# of fragments 0.033010
maximum cap fragment size 0.032459
# of 2-degree acyclic atoms 0.027549
# of 3-degree acyclic atoms 0.021673
# of 3-level bonding patterns 0.018798
total SSSR size 0.017162
total number of 3-8 membered rings 0.017162
# of cyclic fragments 0.016538
# of 1-level bonding patterns 0.016382
# of H-bond donors 0.016217
total number of 3 to 8 unsaturated rings 0.016072
# of aromatic systems 0.014930
# of N with # of H > 0 0.012320
# of hydroxyl groups 0.009301
maximum SSSR size 0.008863
# of linkers 0.008807
# of 2-level bonding patterns 0.006729
total number of 3 to 8 saturated rings 0.004750
Figure 12 Weights of Drug-like features of HIV inhibitors.
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Page 13 of 20application domain, which indicated that for both MTL
and STL the chemical molecules are following a well-
defined domain of applicability. It is worth noting that
for most of those molecules following outside the DOA,
their values of Y axis are generally fall inside the 3s
line, which indicated that, to a large extent, the predic-
tions of our model for the outliers may still be reliable.
In addition, very few compounds in several models
indeed fall outside the 3s line, however, they are close
to the line thus can be retained.
After building the QSAR model, the weight of the DL
features for MTL on 3 HIV datasets, 6 HCV datasets
and all 9 datasets respectively were calculated, Sparse
MTL in this case was trained with 50% of the data for
each task and tested with the remaining data. The fea-
tures ranking were showed in Figure 8, 9 and 10. It
should be noted that the GD feature space will not be
adopted for feature ranking due to its indirectly map-
ping of biological meanings.
Table 2 were concluded from Figure 12, 13 and 14 to
provide a joint feature ranking of the DL compound
descriptors. Top five features were selected to guide our
structure-activity prediction as implemented with struc-
ture-activity report (SAReport) in MOE [27]. These fea-
tures are # of non-H, # of 2-degree acyclic atoms,
degree of cyclization, # of non-H polar bonds and # of
rotatable bonds.
SAReport was applied to present a direct instruction
on how to modify the structure of a compound to make
it to be a better multi-target co-inhibitor of HIV and
HCV. The top structures were selected with their rank-
ing of affinity improvements according to various modi-
f i c a t i o nm e c h a n i s m s .A si n d i c a t e df r o mT a b l e3 ,4 ,5 ,6
and 7, the modifications of compound based on these
structure features are expected to be a feasible way for
efficient multi-target co-inhibitor design. Generally, the
following useful modification strategies were obtained, i.
e., (1) Improving the # of non-H; (2) Improving the # of
2-degree acyclic atoms; (3) Improving the degree of
cyclization; (4) Improving the # of non-H polar bonds
and (5) Improving the # of rotatable bonds. These modi-
fications will improve the binding affinities of HIV and
HCV inhibitors respectively. Such common mechanism
for improving the inhibitor’s affinity on different anti-
Figure 13 Weights of Drug-like features of HCV inhibitors.
Figure 14 Weights of Drug-like features of HIV-HCV inhibitors.
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Page 14 of 20HIV or anti-HCV targets is consistent with our ranking
of joint feature selection obtained by multi-target co-
inhibitors QSAR modelling.
It should be noted that these features are well be com-
monly important for the multiple scaffolds with each
inhibiting an individual target derived from our MTL
model, and they can be necessarily integrated together
to guide the synthesis of a single scaffold against multi-
ple targets, which guarantee that one individual com-
pound could hold its co-inhibitor ability for both virus
targets.
Conclusions
A Multi-target computational screening of HIV-HCV
co-inhibitors with a MTL paradigm was carried out in
o u rs t u d y .C o m p a r e dt oo u rp r e v i o u sw o r k[ 3 1 ] ,i ti s
improved mainly in two aspects: (1) It integrated both
HIV and HCV data sources to enhance significantly the
identification of lead inhibitors for HIV-HCV co-
inhibitor drugs development. (2) A novel accelerated
gradient descent algorithm based MTL model was
incorporated into the multi-target QSAR modeling with
more efficiency in both convergence speed and learning
accuracy. In summary, the computational pipeline pre-
sented here provided an efficient way to identify and
design inhibitors that simultaneously and selectively
bind to multiple targets multiple viruses with high
affinity.
Future researches on multi-target QSAR analysis
could be done to address the compound description
i s s u ew i t hm o r ek i n d so ff e a t ure descriptors. Also the
investigations on the integration and fusion mechanisms
of multi-view feature spaces in compound representa-
tion could be conducted. Recently developed transfer
learning technologies [36] in machine learning commu-
nity may help to handle such cases efficiently. Further-
more, the underline mechanisms of HIV-HCV co-
infection as well as the synthesis of the co-inhibitors
Table 3 More # of non-H, # of non-H polar bonds and # of rotatable bonds could increase the potency of HIV
Protease Inhibitors
Precursor Structure pKi
#17 pKi: 9.28 + 2.11% (× 25.3)
#17 pKi: 9.28 + 2.04% (× 25.3)
#17 pKi: 9.28 + 1.95% (× 25.2)
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Page 15 of 20Table 4 More # of 2-degree cyclic atoms, degree of cyclization and # of non-H polar bonds could increase the potency
of HIV Reverse Transcriptase Inhibitors.
Precursor Structure pKi
#5
log(1/EC50): 8.3
+ 3.88% (× 27.2)
#5
log(1/EC50): 8.3
+ 3.77% (× 26.8)
#5
log(1/EC50): 8.3
+ 3.39% (× 26.4)
#5
log(1/EC50): 8.3
+ 3.39% (× 26.3)
#5
log(1/EC50): 8.3
+ 3.36% (× 26.3)
#5
log(1/EC50): 8.3
+ 3.31% (× 26.6)
#5
log(1/EC50): 8.3
+ 3.32% (× 26.3)
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Page 16 of 20Table 5 More # of non-H, # of 2-degree cyclic atoms, degree of cyclization and # of non-H polar bonds could increase
the potency of HIV Integrase Inhibitors.
Precursor Structure pKi
#11
pIC50: 5.82
+ 0.75%
(× 21.2)
#189
pIC50: 5.53
+ 0.74%
(× 21.2)
#188
pIC50: 4.43
+ 0.73%
(× 21.3)
Table 6 5 More # of non-H, # of non-H polar bonds and # of rotatable bonds could increase the potency of HCV NS5B
Inhibitors
Precursor Structure IC50(uM)NS5B
#15
IC50(uM)NS5B: 1.64
+ 2.51%
(× 25.2)
#15
IC50(uM)NS5B: 1.64
+ 2.18%
(× 24.5)
#15
IC50(uM)NS5B: 1.64
+ 1.63%
(× 27.5)
#15
IC50(uM)NS5B: 1.64
+ 1.19%
(× 24.1)
#15
IC50(uM)NS5B: 1.64
+ 0.98%
(× 24.1)
#15
IC50(uM)NS5B: 1.64
+ 0.91%
(× 24.3)
#15
IC50(uM)NS5B: 1.64
+ 0.79%
(× 24.2)
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Page 17 of 20Table 7 More # of non-H, # of 2-degree cyclic atoms, degree of cyclization and # of non-H polar bonds could increase
the potency of HCV NS3 Inhibitors
Precursor Structure EC50(uM)NS3
#1
EC50(uM)NS3-2: 0.35
+ 1.94%
(× 21.3)
#1
EC50(uM)NS3-2: 0.35
+ 0.55%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.50%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.50%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.37%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.37%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.37%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.33%
(× 17.5)
#1
EC50(uM)NS3-2: 0.35
+ 0.23%
(× 17.5)
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Page 18 of 20based on our study are definitely worthy for long-term
perusing.
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